These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

253 related articles for article (PubMed ID: 26293047)

  • 21. Are serum suPAR determinations by current ELISA methodology reliable diagnostic biomarkers for FSGS?
    Schlöndorff D
    Kidney Int; 2014 Mar; 85(3):499-501. PubMed ID: 24583981
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A reassessment of soluble urokinase-type plasminogen activator receptor in glomerular disease.
    Spinale JM; Mariani LH; Kapoor S; Zhang J; Weyant R; Song PX; Wong HN; Troost JP; Gadegbeku CA; Gipson DS; Kretzler M; Nihalani D; Holzman LB;
    Kidney Int; 2015 Mar; 87(3):564-74. PubMed ID: 25354239
    [TBL] [Abstract][Full Text] [Related]  

  • 23. CD80, suPAR and nephrotic syndrome in a case of NPHS2 mutation.
    Cara-Fuentes G; Araya C; Wei C; Rivard C; Ishimoto T; Reiser J; Johnson RJ; Garin EH
    Nefrologia; 2013; 33(5):727-31. PubMed ID: 24089165
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Circulating urokinase receptor as a cause of focal segmental glomerulosclerosis.
    Wei C; El Hindi S; Li J; Fornoni A; Goes N; Sageshima J; Maiguel D; Karumanchi SA; Yap HK; Saleem M; Zhang Q; Nikolic B; Chaudhuri A; Daftarian P; Salido E; Torres A; Salifu M; Sarwal MM; Schaefer F; Morath C; Schwenger V; Zeier M; Gupta V; Roth D; Rastaldi MP; Burke G; Ruiz P; Reiser J
    Nat Med; 2011 Jul; 17(8):952-60. PubMed ID: 21804539
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Soluble urokinase receptor and focal segmental glomerulosclerosis.
    Reiser J; Wei C; Tumlin J
    Curr Opin Nephrol Hypertens; 2012 Jul; 21(4):428-32. PubMed ID: 22569341
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Management of severe recurrent focal segmental glomerulosclerosis through circulating soluble urokinase receptor modification.
    Morath C; Wei C; Macher-Goeppinger S; Schwenger V; Zeier M; Reiser J
    Am J Ther; 2013; 20(2):226-9. PubMed ID: 23466622
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A multicenter cross-sectional study of circulating soluble urokinase receptor in Japanese patients with glomerular disease.
    Wada T; Nangaku M; Maruyama S; Imai E; Shoji K; Kato S; Endo T; Muso E; Kamata K; Yokoyama H; Fujimoto K; Obata Y; Nishino T; Kato H; Uchida S; Sasatomi Y; Saito T; Matsuo S
    Kidney Int; 2014 Mar; 85(3):641-8. PubMed ID: 24429394
    [TBL] [Abstract][Full Text] [Related]  

  • 28. CD80 and suPAR in patients with minimal change disease and focal segmental glomerulosclerosis: diagnostic and pathogenic significance.
    Cara-Fuentes G; Wei C; Segarra A; Ishimoto T; Rivard C; Johnson RJ; Reiser J; Garin EH
    Pediatr Nephrol; 2014 Aug; 29(8):1363-71. PubMed ID: 24263531
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Circulating suPAR as a biomarker of disease severity in children with proteinuric glomerulonephritis.
    Sołtysiak J; Zachwieja J; Benedyk A; Lewandowska-Stachowiak M; Nowicki M; Ostalska-Nowicka D
    Minerva Pediatr; 2019 Feb; 71(1):4-11. PubMed ID: 27070416
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Soluble Urokinase Receptor Levels in Secondary Focal Segmental Glomerulosclerosis.
    Sun P; Yu L; Huang J; Wang S; Zou W; Yang L; Liu G
    Kidney Dis (Basel); 2019 Oct; 5(4):239-246. PubMed ID: 31768381
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Monitoring suPAR levels in post-kidney transplant focal segmental glomerulosclerosis treated with therapeutic plasma exchange and rituximab.
    Alachkar N; Li J; Matar D; Vujjini V; Alasfar S; Tracy M; Reiser J; Wei C
    BMC Nephrol; 2018 Dec; 19(1):361. PubMed ID: 30558559
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pre-transplant angiotensin receptor II type 1 antibodies and risk of post-transplant focal segmental glomerulosclerosis recurrence.
    Mujtaba MA; Sharfuddin AA; Book BL; Goggins WC; Khalil AA; Mishler DP; Fridell JA; Yaqub MS; Taber TE
    Clin Transplant; 2015 Jul; 29(7):606-11. PubMed ID: 25973696
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Circulating suPAR in two cohorts of primary FSGS.
    Wei C; Trachtman H; Li J; Dong C; Friedman AL; Gassman JJ; McMahan JL; Radeva M; Heil KM; Trautmann A; Anarat A; Emre S; Ghiggeri GM; Ozaltin F; Haffner D; Gipson DS; Kaskel F; Fischer DC; Schaefer F; Reiser J;
    J Am Soc Nephrol; 2012 Dec; 23(12):2051-9. PubMed ID: 23138488
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Significance of the urokinase-type plasminogen activator and its receptor in the progression of focal segmental glomerulosclerosis in clinical and mouse models.
    Chen JS; Chang LC; Wu CZ; Tseng TL; Lin JA; Lin YF; Cheng CW
    J Biomed Sci; 2016 Feb; 23():24. PubMed ID: 26846181
    [TBL] [Abstract][Full Text] [Related]  

  • 35. suPAR and chronic kidney disease-a podocyte story.
    Zeier M; Reiser J
    Pflugers Arch; 2017 Aug; 469(7-8):1017-1020. PubMed ID: 28689240
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Serum suPAR in patients with FSGS: trash or treasure?
    Maas RJ; Deegens JK; Wetzels JF
    Pediatr Nephrol; 2013 Jul; 28(7):1041-8. PubMed ID: 23515666
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The clinical pattern of nephrotic syndrome in children has no effect on the concentration of soluble urokinase receptor (suPAR) in serum and urine.
    Ochocińska A; Jarmużek W; Janas R
    Pol Merkur Lekarski; 2018 Apr; 44(262):183-187. PubMed ID: 29775445
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Has the circulating permeability factor in primary FSGS been found?
    Jefferson JA; Shankland SJ
    Kidney Int; 2013 Aug; 84(2):235-8. PubMed ID: 23903418
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Plasma Soluble Urokinase Receptor Level Is Correlated with Podocytes Damage in Patients with IgA Nephropathy.
    Zhao Y; Liu L; Huang J; Shi S; Lv J; Liu G; Zhao M; Zhang H
    PLoS One; 2015; 10(7):e0132869. PubMed ID: 26167688
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Circulating suPAR levels are affected by glomerular filtration rate and proteinuria in primary and secondary glomerulonephritis.
    Musetti C; Quaglia M; Cena T; Chiocchetti A; Monti S; Clemente N; Magnani C; Dianzani U; Stratta P
    J Nephrol; 2015 Jun; 28(3):299-305. PubMed ID: 25185729
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.